Understand the source comparison
Comparison: SS-LUP-332 vs Established Research Peptides
The following table compares SS-LUP-332's evidence base against peptides with published human safety data. SS-LUP-332 None (zero peer-reviewed studies) Not investigational, not approved Unpublished or speculative Unknown—no Phase 1 data Cannot be recommended o
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares SS-LUP-332's evidence base against peptides with published human safety data.
- SS-LUP-332
- None (zero peer-reviewed studies)
- Not investigational, not approved
- Unpublished or speculative
- Unknown—no Phase 1 data
- Cannot be recommended outside institutional research protocols; safety profile unverified
- BPC-157
- Limited case series, no Phase 3 RCTs
- Not FDA-approved; research-grade only
- Proposed angiogenic and cytoprotective effects via growth factor modulation
- GI disturbances in anecdotal reports; no formal adverse event registry
- Mechanistic rationale exists, but human safety data insufficient for therapeutic claims
- Semaglutide (Wegovy, Ozempic)
- Multiple Phase 3 RCTs published in NEJM, Lancet
- FDA-approved for T2DM and obesity
- GLP-1 receptor agonist; delays gastric emptying, increases satiety
- Nausea (30–45%), vomiting, diarrhoea; rare pancreatitis, gallbladder disease
- Extensively characterised safety profile; known adverse event rates from trials enrolling 5,000+ patients
- Tirzepatide (Mounjaro, Zepbound)
- Phase 3 SURMOUNT and SURPASS trials
- Dual GIP/GLP-1 receptor agonist
- Similar GI profile to semaglutide; hypoglycaemia risk if combined with insulin
- Safety data robust; post-market surveillance ongoing for rare long-term effects